Printer Friendly

THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR

 THERAGENICS ANNOUNCES THIRD QUARTER RESULTS;
 QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
 ATLANTA, Oct. 27 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, for the third quarter ended Sept. 30, 1992, it had a net profit of $373,748, or $.03 per share, a 277 percent improvement on the net profit of $96,463, or $.01 per share, for the third quarter of the preceding year.
 Theragenics' revenue for the third quarter of fiscal 1992 was $1,044,588, a 78 percent gain on the $586,668 in revenue recorded for the same period in fiscal 1991.
 For the first nine months ended Sept. 30, 1992, Theragenics had a net profit of $1,253,376, or $.11 per share, 168 percent greater than the net profit of $465,866, or $.05 per share, for the first three quarters of fiscal 1991. The company's revenue for the first nine months of fiscal 1992 was $3,406,876, an 80 percent improvement on the $1,895,263 compiled for the same period last year.
 Chairman and CEO John W. Herndon stated that increased demand for the company's TheraSeed implant therapy for prostate cancer was chiefly responsible for Theragenics' improved quarterly revenue and profit figures compared to last year.
 Mr. Herndon said he expected further improvements in both profit and revenues with the opening early next year of Theragenics' new production facility.
 Theragenics also developed and licensed TheraSphere, a new therapy for the treatment of liver cancer. TheraSphere is being marketed in Canada by Nordion, one of the world's largest suppliers of radioisotopes.
 THERAGENICS CORP.
 Consolidated Statement of Operations
 (Unaudited)
 Three months ended Sept. 30 1992 1991
 Revenues $1,044,588 $ 586,668
 Net profit 373,748 96,463
 Earnings per common share .03 .01
 Number of shares (in thousands) 11,093 9,879
 Nine months ended Sept. 30: 1992 1991
 Revenues $3,406,876 $1,895,263
 Net profit 1,253,376 465,866
 Earnings per common share .11 .05
 Number of shares (in thousands) 11,117 9,906
 -0- 10/27/92
 /CONTACT: Bruce Smith, chief financial officer of Theragenics Corp., 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics Corp./
 (THRX) CO: Theragenics Corp. ST: Georgia IN: MTC SU: ERN


TS-OS -- NY022 -- 5234 10/27/92 09:29 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1992
Words:386
Previous Article:/C O R R E C T I O N -- Xerox Earnings/
Next Article:PRO-DEX MAY ADD UP TO $400,000 IN MEDI-CAL RECEIPTS DUE TO RECENT COURT RULING ON STATE DENTAL CARE BENEFITS
Topics:


Related Articles
THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
BELLINGHAM INDUSTRIES ACQUIRES 24.1 PERCENT OF THERAGENICS
THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT
THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O.
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS
THERAGENICS ANNOUNCES 1993 RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters